Pompe Disease Registry Protocol
Glycogen Storage Disease Type II | Pompe DiseaseThe Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
0 and up
Participation Criteria
Inclusion Criteria:
All patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and/or documentation of 2 GAA gene mutations.
Exclusion Criteria:
There are no exclusion criteria in this Registry
Study Location
Investigational Site Number : 124010
Investigational Site Number : 124010Vancouver, British Columbia
Canada
Contact Study Team
Investigational Site Number : 124007
Investigational Site Number : 124007Hamilton, Ontario
Canada
Contact Study Team
Investigational Site Number : 124018
Investigational Site Number : 124018Montreal, Quebec
Canada
Contact Study Team
Investigational Site Number : 124002
Investigational Site Number : 124002Edmonton, Alberta
Canada
Contact Study Team
Investigational Site Number : 124022
Investigational Site Number : 124022Moncton, New Brunswick
Canada
Contact Study Team
Investigational Site Number : 124004
Investigational Site Number : 124004Montreal, Quebec
Canada
Contact Study Team
Investigational Site Number : 124011
Investigational Site Number : 124011Vancouver, British Columbia
Canada
Contact Study Team
Investigational Site Number : 124021
Investigational Site Number : 124021London, Ontario
Canada
Contact Study Team
Investigational Site Number : 124001
Investigational Site Number : 124001Sherbrooke, Quebec
Canada
Contact Study Team
Investigational Site Number : 124014
Investigational Site Number : 124014Calgary, Alberta
Canada
Contact Study Team
Investigational Site Number : 124019
Investigational Site Number : 124019Winnipeg, Manitoba
Canada
Contact Study Team
Investigational Site Number : 124006
Investigational Site Number : 124006Toronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Sanofi
- Participants Required
- More Information
- Study ID:
NCT00231400